{"nctId":"NCT00478699","briefTitle":"Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)","startDateStruct":{"date":"2007-06"},"conditions":["Non-small-cell Lung Cancer"],"count":500,"armGroups":[{"label":"1 Control group","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Docetaxel/Cisplatin control"]},{"label":"2 Experimental group","type":"EXPERIMENTAL","interventionNames":["Drug: Docetaxel","Drug: Gemcitabine/Cisplatin","Drug: Docetaxel/Cisplatin"]}],"interventions":[{"name":"Docetaxel/Cisplatin control","otherNames":["Taxotere/Platinol"]},{"name":"Docetaxel","otherNames":["Taxotere"]},{"name":"Gemcitabine/Cisplatin","otherNames":["Gemzar/Platinol"]},{"name":"Docetaxel/Cisplatin","otherNames":["Taxotere/Platinol"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with histological confirmation of non-small-cell lung carcinoma.\n* Complete surgical resection of the disease.\n* Tumoral tissue available for molecular analysis.\n* N1 (stage II) or N2 (stage IIIA) lymph node involvement in the study of the operative piece.\n* Men or women age 18 years or older.\n* Patients with a performance status of 2 or less according to the ECOG classification.\n* Patients with the following laboratory results: ANC \\< 1500/L, Hb \\< 10 g/dL, platelets \\<100,000/L, bilirubin \\< 1.0 mg/dL, AST and ALT \\< 1.5 upper limit of normality, creatinine clearance \\< 60 mL/min.\n* Complete recovery from surgery within 6 weeks.\n* Patients who have given written informed consent before initiating any specific study screening procedure.\n\nExclusion Criteria:\n\n* Patients who have received previously chemotherapy or radiotherapy for the study disease.\n* Impossibility of complying with chemotherapy treatment due to cultural or geographic circumstances.\n* Patients with active infection, heart disease, or any other serious disease, in the judgment of the investigator.\n* Women who are pregnant or in the period of lactation.\n* Patients with a previous diagnosis of malignant disease in the last five years except for carcinoma in situ of the uterine cervix or skin cancer other than melanoma.\n* Patients under treatment with investigational agents.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Estimated Overall Survival","description":"To assess and compare the overall survival estimated at 5 years of both treatment groups (Control arm vs Experimental arm).\n\nOverall survival:The proportion of participants in treatment group who are still alive for a certain period of time after inclusion.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":null},{"groupId":"OG001","value":"0.56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":null},{"groupId":"OG001","value":"0.56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":null},{"groupId":"OG001","value":"0.53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":null},{"groupId":"OG001","value":"0.60","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Free Survival","description":"To assess the disease-free survival of both treatment groups. Disease-free survival: will be calculated from the date of surgery until there is some clinical evidence of disease progression or the date of death due to the disease.","paramType":"MEDIAN","dispersionType":"80% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.7","spread":null},{"groupId":"OG001","value":"32.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":36,"n":108},"commonTop":["Hemoglobin","Asthenia","Nausea","Alopecia","Neutrophils"]}}}